AI-generated analysis. Always verify with the original filing.
On March 13, 2026, GNQ Insilico Inc. entered into a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company to collaborate on sales, marketing, development, and alliance activities for AI-driven drug discovery and precision medicine. The non-exclusive global agreement has an initial two-year term with extension option, integrating GNQ’s AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events Joint Initiative Agreement and Joint Marketing Attachment On March 13, 2026, GNQ Insilico Inc. (“GNQ”) entered into a Joint Initiative Agreement
Material Agreement